Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) EPS (Weighted Average and Diluted) (2016 - 2025)

Regenxbio has reported EPS (Weighted Average and Diluted) over the past 10 years, most recently at -$1.3 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$1.3 for Q4 2025, down 30.0% from a year ago — trailing twelve months through Dec 2025 was -$3.76 (up 18.26% YoY), and the annual figure for FY2025 was -$3.76, up 18.08%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$1.3 at Regenxbio, down from -$1.2 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for RGNX hit a ceiling of $6.84 in Q4 2021 and a floor of -$1.79 in Q1 2022.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$1.38 (2024), compared with a mean of -$0.88.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 651.61% in 2021, while the deepest fall reached 695.65% in 2021.
  • Regenxbio's EPS (Weighted Average and Diluted) stood at $6.84 in 2021, then crashed by 120.32% to -$1.39 in 2022, then fell by 2.16% to -$1.42 in 2023, then grew by 29.58% to -$1.0 in 2024, then decreased by 30.0% to -$1.3 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$1.3 (Q4 2025), -$1.2 (Q3 2025), and -$1.38 (Q2 2025) per Business Quant data.